From Jan. 1, AstraZeneca's Tagrisso (osimertinib) and Yuhan Corp.'s Leclaza (lazertinib) will get health insurance coveraget for the first-line treatment of locally advanced and metastatic non-small cell lung cancer (NSCLC).Koselugo (selumetinib), developed by AstraZeneca and MSD, will be also cover
Once a year, leading medical experts in aesthetics worldwide convene to examine beauty trends, delve into the medico-scientific contributions that medical aesthetics can offer patients, and articulate their vision for elevating the quality of life. The Merz Aesthetics Expert Summit (MEXS) stands as
PharmaEssentia's Besremi (ropeginterferon alfa-2b), a treatment for polycythemia vera (PV), showcased exceptional therapeutic efficacy, achieving complete hematologic and molecular biologic responses in Korean patients who did not respond to hydroxyurea therapy, a study showed. Professor Lee Sung-eu
For decades, platinum-based chemotherapy has been the gold standard for treating locally advanced or metastatic urothelial cancer. However, the advent of antibody-drug conjugates (ADCs) has changed the treatment of urothelial cancer.In addition to providing a new option as a last resort to urothelia
Chronic kidney disease refers to the persistent passage of protein in the urine (proteinuria) or impaired kidney function. Patients with chronic kidney disease are 7.2 times more likely to die than those without it. It is also the disease with the highest medical expenses per patient.According to th
Health insurance coverage for the colon cancer drug Braftovi (encorafenib) is unlikely to be available this year.The National Health Insurance Service (NHIS) and Ono Pharmaceutical recently decided to extend the drug price negotiations for Braftovi after failing to reach a deal by the deadline.Braft
Covid-19 has transitioned from a pandemic to an epidemic, but it continues to mutate and threaten high-risk patients, including those with underlying medical conditions and older adults.Excess deaths have continued to occur in the aftermath of Covid-19 until recently, according to the “Covid-19 Exce
Novartis' PI3K-inhibiting breast cancer drug Piqray (alpelisib) has been struggling in the Korean market, failing to gain access to health insurance coverage.In the meantime, AstraZeneca recently launched a process to win approval in Korea with its FDA-approved AKT inhibitor, capivasertib (Truqap in
With the recent release of the results of the phase 3 studies -- KEYNOTE-859 and KEYNOTE-811 -- of the anti-PD-1 immunotherapy Keytruda (pembrolizumab), immunotherapy is becoming a backbone agent along with conventional chemotherapy in the first-line treatment of advanced gastric cancer, regardless
LEO Pharma's Adtralza (tralokinumab), the second biologic approved to treat atopic dermatitis, and GSK's Trelegy 200 Ellipta (fluticasone/umeclidinium/vilanterol), a triple inhaler asthma medication with an increased steroid dose, have won recognition for reimbursement.In contrast, Antengene's Xpovi
A clinical trial led by a Korean researcher for treating advanced gastric cancer has changed global standards and provided new strategies for designing successful umbrella trials.It was a good example that highlighted the top-notch research capabilities of Korean gastric cancer experts.The American
As drugs demonstrating superior efficacy over existing standard treatments for blood cancers repeatedly failed to get insurance benefits, patients have come forth to call for their swift reimbursement.The Korea Alliance of Patients Organizations delivered an opinion letter to the Health Insurance Re
Handok Pharmaceuticals, which entered the anticancer market for the first time this year, has begun laying the groundwork for a soft landing of its new cancer drugs in Korea.Handok is reportedly running a patient support program to support drug costs for acute myeloid leukemia drug Vyxeos (cytarabin
Starting in November, the health insurance coverage standards will be newly established or expanded for the JAK inhibitors Jyseleca (filgotinib) and Jakavi (ruxolitinib) and the interleukin-5 (IL-5) inhibitors Nucala (mepolizumab) and Cinqair (reslizumab).The Health Insurance Review and Assessment S
Yuhan Corp. has recently revealed the success of the MARIPOSA clinical trial for Leclaza, its third-generation EGFR tyrosine kinase inhibitor (TKI). This development has sparked interest in whether it will mark the first global introduction of a homegrown anticancer drug.Professor Cho Byoung-chul, h
SGLT2 inhibitor Jardiance (empagliflozin) has become a triple-crown treatment option in Korea, adding chronic kidney disease to its existing list of indications of type 2 diabetes and chronic heart failure, following Forxiga (dapagliflozin).Last Thursday, the Ministry of Food and Drug Safety (MFDS)
The first-line treatment strategy for metastatic bladder cancer, where chemotherapy has been the standard of care for the past 30 years, has recently shown signs of rapid reorienting toward immunotherapies and antibody-drug conjugates (ADCs).In particular, the leading anti-PD-1 immunotherapies Keytr
Diffuse Large B Cell Lymphoma (DLBCL) is the most common and aggressive lymphoma subtype. For the past two decades, the standard for the first-line treatment of DLBCL has been the combination therapy known as "R-CHOP" (rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone).Recently, how
Gilead recently launched the first Trop-2-targeted antibody-drug conjugate (ADC), Trodelvy (sacituzumab govitecan), in Korea, providing a new treatment option for patients with metastatic triple-negative breast cancer who have limited options.Gilead began the domestic supply of Trodelvy on Wednesday